All Resources

In this panel Prof. Alice Cheng facilitated a comprehensive discussion with Drs. Sanjoy Dutta, Jeremy Pettus, Jessica Melin, Karin Lange and Renuka Dias. Through role-played scenarios, the speakers explored the T1D care journey from screening and diagnosis to monitoring and management, highlighting the real-world disease burden and the critical importance of early detection. The panel also reviewed current technologies and key decision points that enable effective T1D care.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.

Learn why early detection of T1D in adults matters, why T1D is often missed in dysglycemic adults, its misclassification as T2D, and how islet autoantibody testing supports accurate diagnosis, staging, and timely management. 

Learn why early detection of T1D in children matters, how it reduces DKA risk and supports timely intervention. 

The video discusses the management of patient anxiety after positive T1D islet autoantibody results: Guidance on monitoring, education, and psychosocial support. 

The video discusses the rising T1D burden: Adult-onset misclassification, familial risk, and autoimmune comorbidities impacting diagnosis and management. 

The video discusses how advances in insulin delivery have yet to translate into improved population-level glycemic outcomes

Dr Jeremy Pettus explains how to identify type 1 diabetes (T1D) in adults, avoid misclassification as type 2 diabetes (T2D), and interpret islet autoantibodies (IAbs) and C-peptide to support diagnosis and staging. 

Explore the complex autoimmune cascade that leads to beta cell destruction and development of type 1 diabetes.

The Early-stage T1D: Communication Toolkit is a clear, simple resource for healthcare professionals to support effective, age-appropriate communication with individuals undergoing screening for T1D islet autoantibodies or receiving test results.  

Explore how decades of advancements in biomarkers, genetics, and staging frameworks have culminated in our ability to “see” T1D before symptoms emerge.

Explore how diabetic ketoacidosis (DKA) affects people with T1D and their families, and learn why early detection through autoantibody screening can prevent this crisis. 

In this panel, Dr. Stephen Gitelman facilitated the discussion with Prof Loredana Marcovecchio, Prof Holly O’Donnell, and Prof Jacques Beltrand. The speakers discussed the benefits of early detection of T1D in young people and how insights from screening initiatives can inform global programs, strategies for navigating conversations with individuals considering screening, and the importance of beta-cell preservation in the context of current and emerging therapeutic approaches.

This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.